CXCR4 and B-cell chronic lymphocytic leukemia: Most interestingly, the different intraclonal fractions show variable susceptibility to CLL therapy, since older CXCR4-positive CLL cells (RF and DBF) were observed to be less susceptible to in vivo inhibition by ibrutinib relative to younger cells (190).